EE05288B1 - 7-[4-(4-fluorofenl)-6-isopropl-2-metl(metlsulfonl)amino]primidiin-5-l] -(3R,5S)-3,5- dihdrokshept-6-enohappe kristalsed soolad - Google Patents

7-[4-(4-fluorofenl)-6-isopropl-2-metl(metlsulfonl)amino]primidiin-5-l] -(3R,5S)-3,5- dihdrokshept-6-enohappe kristalsed soolad

Info

Publication number
EE05288B1
EE05288B1 EEP200200445A EEP200200445A EE05288B1 EE 05288 B1 EE05288 B1 EE 05288B1 EE P200200445 A EEP200200445 A EE P200200445A EE P200200445 A EEP200200445 A EE P200200445A EE 05288 B1 EE05288 B1 EE 05288B1
Authority
EE
Estonia
Prior art keywords
methylsulfonyl
fluorophenyl
isopropyl
amino
methyl
Prior art date
Application number
EEP200200445A
Other languages
English (en)
Estonian (et)
Inventor
Philip Taylor Nigel
Okada Tetsuo
Original Assignee
Astrazeneca Ab
Shionogi & Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Shionogi & Co. Ltd. filed Critical Astrazeneca Ab
Publication of EE200200445A publication Critical patent/EE200200445A/xx
Publication of EE05288B1 publication Critical patent/EE05288B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
EEP200200445A 2000-02-15 2001-02-12 7-[4-(4-fluorofenl)-6-isopropl-2-metl(metlsulfonl)amino]primidiin-5-l] -(3R,5S)-3,5- dihdrokshept-6-enohappe kristalsed soolad EE05288B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0003305.0A GB0003305D0 (en) 2000-02-15 2000-02-15 Pyrimidine derivatives
PCT/GB2001/000574 WO2001060804A1 (en) 2000-02-15 2001-02-12 Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid

Publications (2)

Publication Number Publication Date
EE200200445A EE200200445A (et) 2003-12-15
EE05288B1 true EE05288B1 (et) 2010-04-15

Family

ID=9885517

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200445A EE05288B1 (et) 2000-02-15 2001-02-12 7-[4-(4-fluorofenl)-6-isopropl-2-metl(metlsulfonl)amino]primidiin-5-l] -(3R,5S)-3,5- dihdrokshept-6-enohappe kristalsed soolad

Country Status (36)

Country Link
US (2) US6841554B2 (ru)
EP (2) EP1873148B1 (ru)
JP (1) JP4099333B2 (ru)
KR (1) KR100708262B1 (ru)
CN (1) CN1210266C (ru)
AR (1) AR029228A1 (ru)
AT (2) ATE382610T1 (ru)
AU (1) AU775569B2 (ru)
BG (1) BG65562B1 (ru)
BR (1) BR0108378A (ru)
CA (1) CA2397450C (ru)
CO (1) CO5280213A1 (ru)
CY (2) CY1107225T1 (ru)
CZ (1) CZ302136B6 (ru)
DE (2) DE60132178T2 (ru)
DK (2) DK1873148T3 (ru)
EE (1) EE05288B1 (ru)
ES (2) ES2335542T3 (ru)
GB (1) GB0003305D0 (ru)
HK (2) HK1051532A1 (ru)
HU (1) HU228422B1 (ru)
IL (2) IL150807A0 (ru)
IS (1) IS2592B (ru)
MX (1) MXPA02007819A (ru)
MY (1) MY129018A (ru)
NO (1) NO323770B1 (ru)
NZ (1) NZ520032A (ru)
PL (1) PL206729B1 (ru)
PT (2) PT1263739E (ru)
RU (1) RU2265599C2 (ru)
SA (1) SA01220166B1 (ru)
SI (2) SI1263739T1 (ru)
SK (1) SK287144B6 (ru)
UA (1) UA74567C2 (ru)
WO (1) WO2001060804A1 (ru)
ZA (1) ZA200205331B (ru)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
NZ531033A (en) 2001-07-13 2005-07-29 Astrazeneca Uk Ltd Preparation of a 2-(N-methyl-N-methanesulfonylamino)pyrimidine compound or analogous aminopyrimidine compounds
AR039836A1 (es) * 2002-05-21 2005-03-02 Ranbaxy Lab Ltd Proceso para la preparacion de un aldehido de pirimidina util para la preparacion de rosuvastatina
CA2486557A1 (en) * 2002-06-13 2003-12-24 Novartis Ag Calcium salts of indole derived statins
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US7524955B2 (en) 2002-12-16 2009-04-28 Astrazeneca Uk Limited Process for the preparation of pyrimidine compounds
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
WO2005021511A1 (en) * 2003-08-27 2005-03-10 Hetero Drugs Limited A novel process for amorphous rosuvastatin calcium
US7396927B2 (en) 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) * 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
EP1678148A1 (en) * 2003-10-22 2006-07-12 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005077916A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
TW200526596A (en) * 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
EP1689723B1 (en) 2003-12-02 2011-04-27 Teva Pharmaceutical Industries, Ltd. Reference standard for characterization of rosuvastatin
WO2005077917A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
GB0406757D0 (en) * 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
US7179916B2 (en) 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
WO2006035277A2 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
KR100945763B1 (ko) 2005-02-22 2010-03-08 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 제조 방법
CA2499047A1 (en) * 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
EP2508514B1 (en) 2005-06-24 2017-10-18 LEK Pharmaceuticals d.d. Process for preparing amorphous rosuvastatin calcium free of impurities
JP5416403B2 (ja) 2005-06-24 2014-02-12 レツク・フアーマシユーテイカルズ・デー・デー 純粋な非結晶ロスバスタチンカルシウムの調製方法
KR20070062996A (ko) 2005-08-16 2007-06-18 테바 파마슈티컬 인더스트리즈 리미티드 결정성 로수바스타틴 중간체
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
HUE027872T2 (en) * 2006-05-03 2016-11-28 Msn Laboratories Private Ltd A novel process for statins and their pharmaceutically acceptable salts
US7994178B2 (en) 2006-09-18 2011-08-09 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia
WO2008038132A1 (en) * 2006-09-28 2008-04-03 Aurobindo Pharma Limited Crystalline diamine salts of rosuvastatin
WO2008044243A2 (en) 2006-10-09 2008-04-17 Manne Satyanarayana Reddy Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2008067440A2 (en) * 2006-11-29 2008-06-05 Dr. Reddy's Laboratories Ltd. Rosuvastatin dehydroabietylamine salt
HU230981B1 (hu) * 2007-10-12 2019-08-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás rosuvastatin só előállítására
US8653265B2 (en) 2008-05-27 2014-02-18 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
WO2010035284A2 (en) * 2008-09-26 2010-04-01 Matrix Laboratories Ltd An improved process for the preparation of rosuvastatin calcium
EP2387566B1 (en) * 2009-01-14 2014-05-07 KRKA, tovarna zdravil, d.d., Novo mesto Process for the preparation of rosuvastatin
CA2749727A1 (en) 2009-01-15 2010-07-22 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Process for the preparation of rosuvastatin salts
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
HUP0900285A2 (en) 2009-05-07 2011-01-28 Egis Gyogyszergyar Nyilvanosan Mukoedoe Reszvenytarsasag Rosuvastatin salts and preparation thereof
EP2526099B1 (en) 2010-01-18 2016-03-30 MSN Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
CN101935304B (zh) * 2010-06-22 2012-04-18 重庆博腾制药科技股份有限公司 瑞舒伐他汀甘氨酸叔丁酯盐及其制备方法
WO2012063115A2 (en) 2010-11-11 2012-05-18 Jubilant Life Sciences Ltd. Process for the preparation of rosuvastatin calcium via novel amine intermediate
HU230737B1 (hu) 2010-11-16 2018-01-29 EGIS Gyógyszergyár Nyrt Eljárás rosuvastatin só előállítására
HU229260B1 (en) 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
WO2012073256A1 (en) * 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin
HU230987B1 (hu) 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
WO2012176218A1 (en) * 2011-06-24 2012-12-27 Ind-Swift Laboratories Limited Process for preparing rosuvastatin calcium through novel amine salt
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
CN106029895B (zh) 2014-02-06 2021-07-16 株式会社Api 瑞舒伐他汀钙及其中间体的生产方法
CN106397335A (zh) * 2016-08-31 2017-02-15 湖北祥云(集团)化工股份有限公司 瑞舒伐他汀中间体的制备方法
USD841087S1 (en) 2016-11-17 2019-02-19 Ccl Label, Inc. Label sheet with a feed edge assembly
CN109651259B (zh) * 2018-12-29 2020-05-19 浙江永太科技股份有限公司 一种瑞舒伐他汀钙关键中间体的纯化方法
CN111518034A (zh) * 2019-10-21 2020-08-11 山东理工职业学院 他汀类化合物及其中间体的制备方法
CN115417824A (zh) * 2022-09-21 2022-12-02 安徽美诺华药物化学有限公司 一种瑞舒伐他汀中间体的高纯度制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4319039A (en) * 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
DE3063683D1 (en) 1979-08-24 1983-07-14 Beecham Group Plc Amine salt of clavulanic acid, its preparation and use
US4294846A (en) * 1979-09-21 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and products of preparation
JPS56142236A (en) 1980-04-08 1981-11-06 Sankyo Co Ltd Ml-236a and mb-530a derivative
DE3170885D1 (en) * 1980-11-03 1985-07-11 Monsanto Co Tough thermoplastic nylon compositions and processes for preparing them
JPS57185275A (en) 1981-05-07 1982-11-15 Sankyo Co Ltd Tetrahydro-dum-4 and tetrahydro-isodum-4 and their derivatives
US4668699A (en) 1985-08-05 1987-05-26 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4940727A (en) * 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4997848A (en) 1987-10-27 1991-03-05 Sankyo Company, Limited Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
US4868185A (en) * 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
PT89545B (pt) 1988-01-27 1994-02-28 May & Baker Ltd Processo para a preparacao de derivados da isoquinolinona
EP0326388A3 (en) 1988-01-29 1990-11-28 Johnson Matthey, Inc., Waste heat recovery having combined co and nox removal apparatus and method
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089523A (en) 1990-05-11 1992-02-18 E. R. Squibb & Sons, Inc. Fluorinated derivatives of mevinic acids
CA2043525A1 (en) 1990-06-24 1991-12-25 Donald S. Karanewsky Phosphorus-containing hmg-coa reductase inhibitors, new intermediates and method
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP3528186B2 (ja) 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
SI9300296B (sl) 1992-06-11 1998-06-30 Smithkline Beecham P.L.C. Postopek in intermedianti za pripravo klavulanske kisline
US5369123A (en) * 1992-10-09 1994-11-29 E. R. Squibb & Sons, Inc. Nitrogen-substituted mevinic acid derivatives useful as HMG-CoA reductase inhibitors
CA2137049A1 (en) 1993-12-15 1995-06-16 John K. Thottathil Amino acid salts of and methods for preparing antihypercholesterolemic tetrazole compounds
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
SI9500134B (sl) 1995-04-20 2004-04-30 Lek, Postopek za pripravo čistih alkalijskih soli klavulanske kisline
EA000474B1 (ru) 1995-07-17 1999-08-26 Варнер-Ламберт Компани Кристаллическая кислая кальциевая соль [r-(r*, r*)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино)карбонил]-1н-пиррол-1-гептановой кислоты (аторвастатин)
AT403375B (de) 1995-11-15 1998-01-26 Biochemie Gmbh Verfahren zur fällung von alkalisalzen der clavulansäure
SI20070A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
AR022462A1 (es) 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
WO2001004100A1 (en) 1999-07-13 2001-01-18 Lonza Ag Process for preparing 2-amino-4-(4-fluorphenyl)-6-alkylpyrimidine-5-carboxylate
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US6814554B1 (en) * 2003-06-04 2004-11-09 Rechi Precision Co., Ltd. Vortex compressor
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process

Also Published As

Publication number Publication date
DK1263739T3 (da) 2008-03-17
HK1051532A1 (en) 2003-08-08
EP1873148B1 (en) 2009-11-18
UA74567C2 (ru) 2006-01-16
GB0003305D0 (en) 2000-04-05
HUP0204051A2 (en) 2003-05-28
US20060014766A1 (en) 2006-01-19
ZA200205331B (en) 2003-10-03
HUP0204051A3 (en) 2003-07-28
AU775569B2 (en) 2004-08-05
PL206729B1 (pl) 2010-09-30
WO2001060804A1 (en) 2001-08-23
NZ520032A (en) 2004-03-26
SK11742002A3 (sk) 2003-02-04
EP1263739B9 (en) 2008-10-29
IL150807A (en) 2007-07-04
US6841554B2 (en) 2005-01-11
SA01220166B1 (ar) 2006-11-25
HK1055958A1 (en) 2004-01-30
CY1109756T1 (el) 2014-09-10
CN1210266C (zh) 2005-07-13
RU2002124621A (ru) 2004-01-10
JP2003523334A (ja) 2003-08-05
ATE449079T1 (de) 2009-12-15
IS6494A (is) 2002-08-09
KR100708262B1 (ko) 2007-04-17
NO20023853D0 (no) 2002-08-14
BG65562B1 (bg) 2008-12-30
MY129018A (en) 2007-03-30
EP1873148A1 (en) 2008-01-02
RU2265599C2 (ru) 2005-12-10
AR029228A1 (es) 2003-06-18
PT1873148E (pt) 2010-01-20
MXPA02007819A (es) 2004-09-10
CO5280213A1 (es) 2003-05-30
EE200200445A (et) 2003-12-15
CZ20022754A3 (cs) 2002-11-13
BR0108378A (pt) 2003-03-11
SK287144B6 (sk) 2010-01-07
BG106969A (en) 2003-04-30
ES2335542T3 (es) 2010-03-29
CN1418198A (zh) 2003-05-14
DE60132178D1 (de) 2008-02-14
NO20023853L (no) 2002-08-14
ATE382610T1 (de) 2008-01-15
SI1873148T1 (sl) 2010-02-26
DK1873148T3 (da) 2010-03-08
ES2298214T3 (es) 2008-05-16
SI1263739T1 (sl) 2008-04-30
AU3208401A (en) 2001-08-27
CA2397450C (en) 2009-11-17
DE60132178T2 (de) 2008-12-18
CY1107225T1 (el) 2013-04-18
JP4099333B2 (ja) 2008-06-11
PT1263739E (pt) 2008-02-19
NO323770B1 (no) 2007-07-02
IS2592B (is) 2010-03-15
CA2397450A1 (en) 2001-08-23
CZ302136B6 (cs) 2010-11-10
US7129352B2 (en) 2006-10-31
PL356472A1 (en) 2004-06-28
HU228422B1 (en) 2013-03-28
IL150807A0 (en) 2003-02-12
DE60140581D1 (de) 2009-12-31
EP1263739A1 (en) 2002-12-11
EP1263739B1 (en) 2008-01-02
KR20030011771A (ko) 2003-02-11
US20030045718A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
EE05288B1 (et) 7-[4-(4-fluorofenl)-6-isopropl-2-metl(metlsulfonl)amino]primidiin-5-l] -(3R,5S)-3,5- dihdrokshept-6-enohappe kristalsed soolad
NO20013368D0 (no) Krystallinsk bis((E)-7-(4-(4-fluorfenyl)-6-isopropyl-2- (metyl(metylsulfonyl)amino)pyrimidin-5-yl)(3R,5S)-3,5-dihydroksyhept-6-ensyre)kalsiumsalt
SE0002826D0 (sv) Pharmaceutical compositions
IS2820B (is) Samsettar samsetningar sem ná yfir (E)-7-[4-(4-flúorofenýl)-6-ísóprópyl-2-[metýl(metýlsúlfónýl)-amínó]pýrimídín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru
TWI341310B (en) Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt
TWI370817B (en) Novel crystalline form of bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[ methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt,and relevant manufacture process, pharmaceutical composition, and use

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20160212